| Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial S Tepper, M Ashina, U Reuter, JL Brandes, D Doležil, S Silberstein, ... The Lancet Neurology 16 (6), 425-434, 2017 | 811 | 2017 |
| Origin of pain in migraine: evidence for peripheral sensitisation J Olesen, R Burstein, M Ashina, P Tfelt-Hansen The Lancet Neurology 8 (7), 679-690, 2009 | 654 | 2009 |
| ARISE: a phase 3 randomized trial of erenumab for episodic migraine DW Dodick, M Ashina, JL Brandes, D Kudrow, M Lanteri-Minet, V Osipova, ... Cephalalgia 38 (6), 1026-1037, 2018 | 588 | 2018 |
| Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura JM Hansen, AW Hauge, J Olesen, M Ashina Cephalalgia 30 (10), 1179-1186, 2010 | 524 | 2010 |
| Migraine: epidemiology and systems of care M Ashina, Z Katsarava, TP Do, DC Buse, P Pozo-Rosich, A Özge, ... The Lancet 397 (10283), 1485-1495, 2021 | 480 | 2021 |
| PACAP38 induces migraine-like attacks in patients with migraine without aura HW Schytz, S Birk, T Wienecke, C Kruuse, J Olesen, M Ashina Brain 132 (1), 16-25, 2009 | 476 | 2009 |
| A systematic comparison of motion artifact correction techniques for functional near-infrared spectroscopy RJ Cooper, J Selb, L Gagnon, D Phillip, HW Schytz, HK Iversen, M Ashina, ... Frontiers in neuroscience 6, 147, 2012 | 455 | 2012 |
| Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled … DW Dodick, PJ Goadsby, SD Silberstein, RB Lipton, J Olesen, M Ashina, ... The lancet neurology 13 (11), 1100-1107, 2014 | 452 | 2014 |
| Migraine and the trigeminovascular system—40 years and counting M Ashina, JM Hansen, TP Do, A Melo-Carrillo, R Burstein, MA Moskowitz The Lancet Neurology 18 (8), 795-804, 2019 | 409 | 2019 |
| Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial H Sun, DW Dodick, S Silberstein, PJ Goadsby, U Reuter, M Ashina, ... The Lancet Neurology 15 (4), 382-390, 2016 | 406 | 2016 |
| European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention S Sacco, L Bendtsen, M Ashina, U Reuter, G Terwindt, DD Mitsikostas, ... The journal of headache and pain 20, 1-33, 2019 | 402 | 2019 |
| Migraine and structural changes in the brain: a systematic review and meta-analysis A Bashir, RB Lipton, S Ashina, M Ashina Neurology 81 (14), 1260-1268, 2013 | 385 | 2013 |
| Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind … MD Ferrari, HC Diener, X Ning, M Galic, JM Cohen, R Yang, M Mueller, ... The Lancet 394 (10203), 1030-1040, 2019 | 383 | 2019 |
| Evidence for a vascular factor in migraine MS Asghar, AE Hansen, FM Amin, RJ Van Der Geest, P Koning, ... Annals of neurology 69 (4), 635-645, 2011 | 366 | 2011 |
| Magnetic resonance angiography of intracranial and extracranial arteries in patients with spontaneous migraine without aura: a cross-sectional study FM Amin, MS Asghar, A Hougaard, AE Hansen, VA Larsen, ... The Lancet Neurology 12 (5), 454-461, 2013 | 365 | 2013 |
| Diagnosis and management of migraine in ten steps AK Eigenbrodt, H Ashina, S Khan, HC Diener, DD Mitsikostas, AJ Sinclair, ... Nature Reviews Neurology 17 (8), 501-514, 2021 | 354 | 2021 |
| Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1) M Ashina, J Saper, R Cady, BA Schaeffler, DM Biondi, J Hirman, ... Cephalalgia 40 (3), 241-254, 2020 | 341 | 2020 |
| Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults C Tassorelli, HC Diener, DW Dodick, SD Silberstein, RB Lipton, M Ashina, ... Cephalalgia 38 (5), 815-832, 2018 | 317 | 2018 |
| Nitric oxide synthase inhibition in migraine LH Lassen, M Ashina, I Christiansen, V Ulrich, J Olesen The Lancet 349 (9049), 401-402, 1997 | 316 | 1997 |
| Vasoactive intestinal peptide causes marked cephalic vasodilation, but does not induce migraine A Rahmann, T Wienecke, JM Hansen, J Fahrenkrug, J Olesen, M Ashina Cephalalgia 28 (3), 226-236, 2008 | 308 | 2008 |
Jes OlesenProfessor i Neurologi在 regionh.dk 的电子邮件经过验证
